# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

#### **SCHEDULE 14A**

(Rule 14a-101)

## INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed l	by the R	.egistrant ⊠	Filed by a Party other than the Registrant $\square$						
Check	the app	propriate box:							
	Prelim	inary Proxy Stateme	nt						
	Confi	dential, for Use of tl	ne Commission Only (as permitted by Rule 14a-6(e)(2))						
	Defini	tive Proxy Statemen							
$\boxtimes$	Defini	Definitive Additional Materials							
	Solicit	nt to § 240.14a-12							
			ZIOPHARM Oncology, Inc. (Name of Registrant as Specified in Its Charter)						
			(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)						
Payme	ent of Fi	ling Fee (Check the	appropriate box):						
$\boxtimes$	No fee	e required.							
	Fee co	omputed on table belo	ow per Exchange Act Rules 14a-6(i)(1) and 0-11.						
	(1)	(1) Title of each class of securities to which transaction applies:							
	(2)	Aggregate number of securities to which transaction applies:							
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on whice filing fee is calculated and state how it was determined):							
	(4)	Proposed maximum aggregate value of transaction:							
	(5)	Total fee paid:							
	Fee pa	aid previously with p	reliminary materials:						
	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was								
	paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.								
	(1)	Amount previously	paid:						
	(2)	Form, Schedule or Registration Statement No.:							
	(3)	Filing Party:							
	(4)	Date Filed:							

### Your Vote Counts!

ZIOPHARM ONCOLOGY, INC.

2021 Annual Meeting Vote by May 18, 2021 11:59 PM ET

ZIOPHARM ONCOLOGY, INC. ATIN: CORPORATE SECRETARY ONE FIRST AVENUE, PARRIS BLDG #34 THRD FLOOR, NAVY YARD PLAZA BOSTON, MA 02129



#### You invested in ZIOPHARM ONCOLOGY, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on May 19, 2021.

#### Get informed before you vote

View the Notice & Proxy Statement, Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 05, 2021. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #

#### **Smartphone users**

Point your camera here and vote without entering a control number





Vote Virtually at the Meeting\*
May 19, 2021

9:00 AM EDT

Virtually at: www.virtualshareholdermeeting.com/ZIOP2021

<sup>\*</sup>Please check the meeting materials for any special requirements for meeting attendance.

### Vote at www.ProxyVote.com

#### THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

Voting Items									
1.	Elect	Election of Directors							
	Nominees:								
	01)	Christopher Bowden	04)	Robert W. Postma	07)	Holger Weis	<b>⊘</b> For		
	02)	Heidi Hagen	05)	Mary Thistle					
	03)	James Huang	06)	Jaime Vieser					
2.	To ratify the selection by the audit committee of the board of directors of RSM US LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021.								
3.	To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement.								
4.	To approve an amendment to the Company's amended and restated certificate of incorporation to increase the authorized number of shares of common stock from 250,000,000 shares to 350,000,000 shares.								
	E. To	transact any other business	as may pro	perly come before the me	eting or any	adjournments or postponements t	hereof.		

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Sign up for E-delivery".